The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's ...

Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...

The Maple Ridge resident was surprised considering, as he has since learned, multiple myeloma is the second most prevalent ...

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

An international study led by the Spanish National Cancer Research Centre (CNIO) and the 12 de Octubre Hospital in Madrid ...

The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...

Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...

This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.

The FDA has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone for transplant-ineligible, newly diagnosed multiple myeloma.

A Boulder woman is opening up about her fight with multiple myeloma during Blood Cancer Awareness Month. She went from being ...

When Mags Kirwan was first diagnosed with multiple myeloma three years ago, she made the conscious decision to “run her own ...